On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ACADEMIA
ACADEMIA
- Prof. Nakamura Renews Call for Establishment of Drug Discovery Support Organization
March 9, 2012
- Insulin Stockpiles Insufficient at Medical Facilities in Disaster-Hit Areas: JDS Survey
March 6, 2012
- Osaka Medical Center President Hori says “Once-Daily Xarelto is Easy to Take”
February 27, 2012
- JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL
February 7, 2012
- Demand for Celecox Expected to Increase for Acute Pain Relief: Prof. Ishiguro
January 26, 2012
- Manufacturers Report on Patient Benefits of Oral RI Drugs
January 24, 2012
- JDS to Use NGPS Score for HbA1c in Clinical Practices from April
January 23, 2012
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
- JUA Negative about OTC Switching of Propiverine Hydrochloride
November 17, 2011
- PSJ Preparing for Exchange of Views with JAMS on Switch-OTC Drug Candidates
November 15, 2011
- Teriparatide “Strongly Recommended” for Non-vertebral Fracture: JOS Draft GLs
November 7, 2011
- “No Major Ethnic Differences” in Pharmacokinetics of 3 Drugs Reported
November 1, 2011
- JSGM Calls for Elimination of GE Drug Refusal Option in Prescriptions
October 28, 2011
- JSGM Calls For Elimination of GE Drug Refusal Option in Prescriptions
October 27, 2011
- “No Major Differences” Between 4 AD Treatments; More Evidence Needed: Prof. Hanyu
October 20, 2011
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…